EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)Open Access

Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study

Yuanyuan Zhao, Hongyun Zhao iD, Qiming Wang iD, Kunyu Yang iD, Yongsheng Li iD, Zhenming Fu iD, Weihua Yang, Zhiyong He, Yongsheng Wang, Yuxiang Ma iD, Yunpeng Yang, Wenfeng Fang iD und 5 weitere

Journal of Clinical Oncology · 01.10.2026 · 44 (28) · 2670-2679

DOI: 10.1200/jco-26-00243 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.10.2026. Verfasst von Yuanyuan Zhao und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Cente…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Immunoconjugates, Lung Neoplasms, Receptor, ErbB-3. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Small cell lung cancer (SCLC) remains one of the most aggressive malignancies, with limited treatment options beyond frontline chemo-immunotherapy. Izalontamab brengitecan (iza-bren, BL-B01D1) is a first-in-class bispecific antibody-drug conjugate cotargeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). We expanded the SCLC cohort to further evaluate the efficacy and safety of iza-bren in patients with extensive-stage SCLC (ES-SCLC). METHODS This open-label, multicenter, dose-expansion phase Ib study (ClinicalTrials.gov identifier: NCT05194982 ) enrolled patients with ES-SCLC who had progressed on prior systemic therapies. Patients received iza-bren 2.5 mg/kg once daily on days 1 and 8 of each 3-week cycle. The primary end points were objective response rate (ORR) and safety/tolerability. Secondary end points included disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS). Exploratory end point included the assessment of potential associations between EGFR/HER3 expression and clinical outcomes. RESULTS As of December 5, 2024, 52 patients were enrolled. The ORR was 48.1% (95% CI, 34.0 to 62.4), with a median PFS of 4.1 months (95% CI, 3.0 to 5.5) and a median OS of 12.2 months (95% CI, 9.1 to 13.2). In patients who received iza-bren as second-line treatment (n = 22), the ORR was 72.7% (95% CI, 49.8 to 89.3), median PFS 6.2 months (95% CI, 3.7 to 8.2), and median OS 15.0 months (95% CI, 8.7 to not reached). The most common treatment-related adverse events were hematologic toxicities (neutropenia, thrombocytopenia, anemia, and leukopenia). Exploratory biomarker analysis suggested that positive HER3 expression may be associated with better treatment response. CONCLUSION Iza-bren showed encouraging antitumor activity in relapsed ES-SCLC, particularly in the second-line setting. A phase III randomized controlled trial of iza-bren compared with topotecan (ClinicalTrials.gov identifier: NCT06500026 ) is ongoing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificImmunoconjugatesLung NeoplasmsReceptor, ErbB-3Small Cell Lung CarcinomaAdultAgedFemaleHumansMaleMiddle AgedErbB ReceptorsNeoplasm StagingProgression-Free Survival

Substanzen

Antibodies, BispecificEGFR protein, humanErbB ReceptorsERBB3 protein, humanImmunoconjugatesReceptor, ErbB-3

Autor:innen und Institutionen

  • Department of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center f…
  • Department of Clinical Research, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center…
  • Department of Internal Medicine, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Institute of Cancer Research, Henan Academy of Innovations in Medical Science, Zhengzhou, China.
  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing, China.
  • Cancer Center, Renmin Hospital of Wuhan University, Wuhan, China.

ORCID-Profile: Hongyun Zhao, Qiming Wang, Kunyu Yang, Yongsheng Li, Zhenming Fu, Yuxiang Ma, Wenfeng Fang, Hai Zhu, Li Zhang, Yan Huang

Zitieren

APA

Zhao, Y., Zhao, H., Wang, Q., Yang, K., Li, Y., Fu, Z., Yang, W., He, Z., Wang, Y., Ma, Y., Yang, Y., Fang, W., Xiao, S., Zhu, H., Zhu, Y., Zhang, L., & Huang, Y. (2026). Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. Journal of Clinical Oncology, 44(28), 2670-2679. https://doi.org/10.1200/jco-26-00243

Vancouver

Zhao Y, Zhao H, Wang Q, Yang K, Li Y, Fu Z, et al. Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. Journal of Clinical Oncology. 2026;44(28):2670-2679. doi:10.1200/jco-26-00243

BibTeX
@article{Zhao2026,
  author = {Zhao, Yuanyuan and Zhao, Hongyun and Wang, Qiming and Yang, Kunyu and Li, Yongsheng and Fu, Zhenming and Yang, Weihua and He, Zhiyong and Wang, Yongsheng and Ma, Yuxiang and Yang, Yunpeng and Fang, Wenfeng and Xiao, Sa and Zhu, Hai and Zhu, Yi and Zhang, Li and Huang, Yan},
  title = {Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {28},
  pages = {2670--2679},
  doi = {10.1200/jco-26-00243}
}
Kostenlos starten →